Why the study?
The issue of preventing calcification in cardiovascular bioprostheses has not yet been settled, motivating a review of the mechanisms and prospects of using bisphosphonates for bioprosthesis modification.
Do bisphosphonates prevent calcification in bioprosthetic heart valves?
Do bisphosphonates prevent calcification in bioprosthetic heart valves?
Bisphosphonates represent a potential pharmacological strategy for preventing calcification in bioprosthetic heart valves.
Enhances molecular insights into bisphosphonates; leaves open their evolving role in calcium disorder management.
As early as 50 years ago, bisphosphonates turned from a water treatment agent into one of the most widely used groups of drugs for the treatment of various diseases of calcium metabolism (bone tissue resorption, oncological complications of neurodegenerative diseases and others). Years of research on bisphosphonates have contributed to the understanding of their molecular and cellular pathways of their action. All bisphosphonates have a similar structure and common properties, however, there are obvious chemical, biochemical, and pharmacological differences between them. Each bisphosphonate has its own unique profile. This review summarizes data on the mechanisms of action of bisphosphonates, demonstrates the experience and prospects for their use for the modification of cardiovascular bioprostheses, since the issue of preventing bisphosphonate calcification has not been settled yet.
No takes yet. Share an insight, caveat, or question.
T.P. Timchenko (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: